Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($)		Series A Preferred Stock	Class A Common Stock		Class B Common Stock	Additional Paid-in-Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interests	Total
Balance at Dec. 31, 2020						$ 142,346,852	$ (87,300,472)	$ (48,539)	$ 11,949,200	$ 66,947,041
Balance (in Shares) at Dec. 31, 2020		28,055	35,497		55,008
Effect of reverse acquisition
Effect of reverse acquisition (in Shares)		18,099,548	22,900,719		35,488,938
Conversion of share due to merger recapitalization			$ 7,649							7,649
Conversion of share due to merger recapitalization (in Shares)		(18,099,548)	(22,900,719)		(35,488,938)
Effect of reverse acquisition			$ 7,649			142,346,852	(87,300,472)	(48,539)	11,949,200	66,954,690
Effect of reverse acquisition (in Shares)			76,489,205
Share issued for services			$ 17							17
Share issued for services (in Shares)			171,608
Stock based compensation						391,534				391,534
Noncontrolling interest contribution									333,025	333,025
Foreign currency translation								7,998		7,998
Net loss attributable to Noncontrolling interests									(320,632)	(320,632)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries							(1,678,364)			(1,678,364)
Balance at Mar. 31, 2021			$ 7,666			142,738,386	(88,978,836)	(40,541)	11,961,593	65,688,268
Balance (in Shares) at Mar. 31, 2021			76,660,813
Stock based compensation						370,000				370,000
Foreign currency translation								94,655		94,655
Net loss attributable to Noncontrolling interests									1,748,223	1,748,223
Net income attributable to stockholders of DocGo Inc. and Subsidiaries							(1,646,216)			(1,646,216)
Balance at Jun. 30, 2021			$ 7,666			143,108,386	(90,625,052)	54,114	13,709,816	66,254,930
Balance (in Shares) at Jun. 30, 2021			76,660,813
Balance at Dec. 31, 2021			$ 10,013	[1]		283,161,216	(63,556,714)	(32,501)	7,475,010	227,057,024
Balance (in Shares) at Dec. 31, 2021			100,133,953	[1]
UK Ltd. Restricted Stock			$ 8	[1]		82,297				82,305
UK Ltd. Restricted Stock (in Shares)			8,258	[1]
Exercise of stock options			$ 195	[1]		374,149				374,344
Exercise of stock options (in Shares)			195,152	[1]
Stock based compensation				[1]		1,422,937				1,422,937
Equity cost						(19,570)				(19,570)
Noncontrolling interest contribution				[1]					2,063,000	2,063,000
Foreign currency translation				[1]				(5,863)		(5,863)
Net loss attributable to Noncontrolling interests				[1]					(1,257,257)	(1,257,257)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries				[1]			10,629,694			10,629,694
Balance at Mar. 31, 2022			$ 10,208	[1]		284,938,732	(52,927,020)	(38,364)	8,280,753	240,264,309
Balance (in Shares) at Mar. 31, 2022			100,329,105	[1]
Common stock repurchased			$ (70)	[1]		(497,829)				(497,899)
Common stock repurchased (in Shares)	[1]		(70,000)
Exercise of stock options			$ 418	[1]		778,648				779,066
Exercise of stock options (in Shares)			417,927	[1]
Stock based compensation				[1]		1,999,619				1,999,619
Foreign currency translation				[1]				10,434		10,434
Net loss attributable to Noncontrolling interests				[1]					(979,791)	(979,791)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries				[1]			12,735,653			12,735,653
Balance at Jun. 30, 2022			$ 10,564	[1]		$ 287,301,467	$ (40,191,367)	$ (27,930)	$ 7,300,962	$ 254,393,696
Balance (in Shares) at Jun. 30, 2022			100,685,290	[1]

[1] References to Class A Common Stock after November 5, 2021 refer to common stock of DocGo Inc., par value $0.0001. See Note 1, “Description of Organization and Business Operations” to the Condensed Consolidated Financial Statements for additional information.